PharmaTelevision - Apposite Capital: Ready to Take the Lead in Life Science Investments

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Apposite Capital: Ready to Take the Lead in Life Science Investments

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this interview, Fintan Walton talks to Dr. Allan Marchington, partner in Apposite Capital, an independent single sector fund located in London but established with funding from the Mizuho Financial Group, one of Japan’s largest financial services company. Focusing on health care services in the UK and on life sciences in Europe and the U.S., Apposite uses their well-established network of executives and entrepreneurs to first identify and then to take the lead as early stage investors. A nine year fund, Apposite is endowed with $200 million to invest and, to date, have invested about 50% of their fund. Dr. Marchington shares that their success is built on their systematic approach to identifying areas of investment, their diligent efforts to work closely with early-stage companies, and their top-notch Advisory Board selected from some of the world’s top pharma companies.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Venture funds from Japan.

Fintan Walton:

Hello and welcome to PharmaVentures Business Review here in Madrid. On this show I have Allan Marchington, who is a Partner at Apposite Capital. Welcome to the show.

Allan Marchington:

Thank you. It's great.

Fintan Walton:

Apposite Capital is based in London yet its funds which is a venture capital fund is from Japan?

Allan Marchington:

Correct.

Fintan Walton:

You've raised over $200 million, why Japan for your funds?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Allan Marchington

Partner

Dr. Allan Marchington is a partner in Apposite Capital and is responsible for Apposite's Life Sciences investments. A partner since its inception, Dr. Marchington is a well-known executive in the pharmaceuticals sector and previously worked at Abingworth Management, where he was responsible for strategic changes at several of their portfolio companies. He joined Abingworth in 2003, from Millennium Pharmaceuticals, Cambridge MA, where as a member of the senior management team he was responsible for Millennium's European activities and all of the company's technology investments. Prior to Millennium, Dr. Marchington was principal founder and CEO of Cambridge Combinatorial, a combinatorial chemistry company that was acquired by Millennium for a substantial multiple of invested capital. He has a PhD in Chemistry from the University of Liverpool.

Apposite Capital

Apposite is a single sector fund investing in both life sciences and healthcare services on an international basis. Based in London, Apposite was established by the Mizuho Financial Group, one of Japan's largest financial services companies. The members of the Apposite team have a highly synergistic mix of healthcare venture/private equity, entrepreneurship, management and investment banking experience spanning many decades. Apposite also benefits from an established global network of leading advisors covering all aspects of the global healthcare market. The fund's strategy is to leverage the capabilities of the team and its advisors, combined with the fund's extensive range of contacts in Japan, Europe and the US to continuously add value to its portfolio companies.